Literature DB >> 12425507

Thiazolidinediones: a review of their benefits and risks.

Fernando Ovalle1, Ovalle-Berúmen J Fernando.   

Abstract

Several new drugs have become available for the treatment of type 2 diabetes mellitus in the past few years, and among them the thiazolidinediones are probably the most promising and interesting. Their mechanism of action involves a reduction in insulin resistance while simultaneously improving some of the independent risk factors for cardiovascular disease frequently found in patients with type 2 diabetes mellitus. On the other hand, while they might have many advantages over the other available antihyperglycemic agents, there are still some concerns about their long-term safety. Consequently, while awaiting the results of the planned long-term cardiovascular outcome studies, which will help establish their true benefits and risks, physicians must remain skeptical about these drugs and consider not only their claimed advantages, but also their not-so-well-publicized risks. This article summarizes the known and/or presumed beneficial and toxic effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12425507

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Association of hepatocellular carcinoma with thiazolidinediones use: A population-based case-control study.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.